FrancophonIA/ELRC3.0 huggingface dataset:
English: Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine.
Maltese: Hemm tagħrif minn studju ta' trattament fit-tul, f'pazjenti negattivi għall-HbeAg (NUCAB3017) li rċevew trattament b'lamivudine.
English: Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 60-70 times higher than the anticipated clinical plasma levels.
Maltese: Lamivudine ma kienx ġenotossiku in vivo f'dożi li rriżultaw f'konċentrazzjonijiet ta' plażma 60-70 darba iktar mill-livelli ta' plażma klinikament antiċipati.
English: HBV viral subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have been identified with extended therapy.
Maltese: Subpopolazzjonijiet ta' HBV virali b'suxxettibilita' mnaqqsa għal lamivudine (mutant YMDD talHBV) ġew identifikati wara terapija fit-tul.
English: In patients with YMDD mutant HBV, 18/39 (46 %) had improvements in necroinflammatory activity and 9/39 (23 %) had worsening.
Maltese: F'pazjenti bil-mutant YMDD tal-HBV, 18/39 (46 %) kellhom titjib flattività nekro-infjammatorja u 9/39 (23 %) marru għal-agħar.
English: After two years of treatment in this study, ALT normalisation and undetectable HBV DNA occurred in 30/69 (43 %) and 32/68 (47 %) patients respectively and improvement in necroinflammatory score in 18/49 (37 %) patients.
Maltese: Wara sentejn ta' trattament f'dan l-istudju, kien hemm normalizzazzjoni ta' ALT u HBV DNA li ma jkunx osservat f'30/69 (43 %) u 32/68 (47 %) pazjent rispettivament u titjib fl-iskore nekro-infjammatorju f'18/49 (37 %) pazjent.
English: Patients with ALT Elevation/ Patients with Observations*
Maltese: Pazjenti b'osservazzjonijiet*
English: Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85 %.
Maltese: Assorbiment Lamivudine hu assorbit sew mill-parti gastro-intestinali, u l-biodisponibilita' ta' lamivudine li jittieħed mill-ħalq minn adulti hi normalment bejn 80% u 85%.
English: Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses.
Maltese: Soppressjoni virali nżammet (studju NUC20917 ta' wara) b'terapija kkombinata fit-tieni sena ta' kura sa ġimgħa 104 bil-pazjenti jibqgħu jkollhom titjib kontinwu fir-risponsi viroloġiċi u bijokimiċi.
English: Zeffix is used to treat long term (chronic) hepatitis B infection in adults.
Maltese: Zeffix jintuża biex jikkura infezzjoni fit-tul (kronika) tal-epatite B fl-adulti.
English: The bottle contains 240 ml of lamivudine solution (5 mg/ml).
Maltese: Il-flixkun ikun fih 240 ml tas-soluzzjoni ta' lamivudine (5 mg/ml).
English: The frequency categories assigned to the adverse reactions are mainly based on experience from clinical trials including a total of 1,171 patients with chronic hepatitis B receiving lamivudine at 100mg.
Maltese: Il-kategoriji ta' frekwenza marbutin mar-reazzjonijiet avversi huma primarjament ibbażati fuq esperjenza minn provi kliniċi inkluż total ta' 1,171 pazjent b'epatite B kronika li kienu qed jingħataw lamivudine b'doża ta' 100 mg.
English: In patients with YMDD mutant HBV, 41/82 (50 %) patients had improvement in liver inflammation and 40/56 (71 %) patients without YMDD mutant HBV had improvement.
Maltese: F'pazjenti bil-mutant YMDD tal-HBV, 41/82 (50%) pazjent kellhom titjib flinfjammazzjoni tal-fwied u 40/56 (71%) pazjent mingħajr il-mutant YMDD tal-HBV kellhom titjib.
English: Frequency categories are only assigned to those adverse reactions considered to be at least possibly causally related to lamivudine.
Maltese: Kategoriji ta' frekwenza jingħataw biss għal dawk ir-reazzjonijiet aversi kkunsidrati li jkunu għallinqas possibilment ikkaġunati minn lamivudine.
English: ALT  3 x baseline value†
Maltese: ALT ≥ 3 x valur linja bażi†
English: The tablets are butterscotch coloured, capsule shaped, biconvex and engraved “GX CG5” on one side.
Maltese: Għandhom forma ta' kapsula u ta' lewn butterscotch (kannella ċar), ibbuzzati fuq iż-żewġ naħat u mnaqqxa bi “GX CG5” fuq naħa waħda.
English: • medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly
Maltese: • mediċini (normalment likwidi) li fihom sorbitol jew alkoħol taz-zokkor ieħor (bħal xylitol, mannitol, lactitol jew maltitol), jekk jittieħdu regolarment
English: A common side effect (these may affect up to 1 in 10 people) is:
Maltese: Effett sekondarju komuni (dan jista' jaffettwa sa persuna waħda minn kull 10) huwa:
English: The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlipasemia).
Maltese: L-effetti avversi l-aktar komuni li kienu rrappurtati jinkludu mard fid-demm (anemija, newtropenja) u mard metaboliku (iperlajpejżimja).
English: The observed half-life of elimination is 5 to 7 hours.
Maltese: In-nofs ħajja (half life) tat-tneħħija osservata hi minn 5 sa 7 sigħat.
English: The pack also includes a polyethylene applicator-adapter, and a 10 ml oral applicator comprised of a polypropylene barrel (with ml graduations) and a polyethylene plunger.
Maltese: Il-pakkett fih ukoll adapter-applikatur tal-polyethylene, u applikatur ta' 10ml biex magħmul minn miżura ta' kapaċita' tal-polyethylene (bil-gradwazzjonijiet tal-ml) u planġer tal-polyethylene.
English: Clinical resistance
Maltese: Reżistenza klinika
English: Muscle disorders, including myalgia and cramps*
Maltese: Disturbi fil-muskoli, inklużi majalġja u bugħawwieġ*
English: In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting.
Maltese: In vitro lamivudine jinibixxi l-fosforizzazzjoni intraċellulari ta' cladribine u b'hekk iwassal għal riskju potenzjali ta' telf tal-effikaċja ta' cladribine fil-każ li jittieħdu flimkien fl-ambjent kliniku.
English: HBeAg seroconversion
Maltese: Bijotrasformazzjoni
English: MARKETING AUTHORISATION NUMBER EU/1/99/114/003
Maltese: EU/1/99/114/001 EU/1/99/114/002
English: Zeffix contains sugar and preservatives
Maltese: Zeffix fih zokkor u preservattivi
English: Those with HBV DNA levels greater than 200 copies/mL at 6 months (24 weeks) of lamivudine therapy had a 60 % chance of developing the YMDD mutant compared with 8 % of those with HBV DNA levels less than 200 copies/mL at 24 weeks of lamivudine therapy.
Maltese: Dawk b'livelli ta' HBV DNA ogħla minn 200 kopja/mL wara 6 xhur (24 ġimgħa) ta' terapija b'lamivudine kellhom ċans ta' 60% li jiżviluppaw il-mutant YMDD meta mqabbel ma' 8% ta' dawk b'livelli ta' HBV DNA inqas minn 200 kopja/mL wara 24 ġimgħa ta' terapija b'lamivudine.
English: Zeffix is indicated for the treatment of chronic hepatitis B in adults with:
Maltese: Zeffix hu indikat għall-kura tal-epatite B kronika f'adulti li għandhom:
English: Lamivudine has been administered to children and adolescents with compensated CHB in a placebo controlled study of 286 patients aged 2 to 17 years.
Maltese: Lamivudine ingħata lil tfal u adolexxenti b'CHB ikkumpensat fi studju kkontrollat bi plaċebo f'286 pazjenti bejn sentejn u 17-il sena.
English: Confirmed HBeAg seroconversion occurred in 47 % (118/252) of subjects treated with lamivudine and 93 % (320/345) of subjects receiving lamivudine became HBV DNA negative (VERSANT [version 1], bDNA assay, LLOD < 0.7 MEq/ml) during the study.
Maltese: Serokonverżjoni ta' HBeAg ikkonfermata seħħet f'47 % (118/252) ta' suġġetti li rċevew trattament b'lamivudine u 93 % (320/345) ta' suġġetti li kienu qed jirċievu lamivudine saru negattivi għal HBV DNA
English: How much to take The usual dose of Zeffix is 20 ml (100 mg lamivudine) once a day.
Maltese: Id-doża tas-soltu ta' Zeffix hija 20 ml (100 mg lamivudune) darba kuljum.
English: In patients without the mutant, 20/27 (74 %) had improvements in necroinflammatory activity and 2/27 (7 %) had worsening.
Maltese: F'pazjenti mingħajr il-mutant, 20/27 (74 %) kellhom titjib fl-attività nekro-infjammatorja u 2/27 (7 %) marru għal-agħar.
English: In patients with the mutant, 4/26 (15 %) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pretreatment.
Maltese: F'pazjenti bil-mutant, 4/26 (15 %) pazjenti wrew titjib fl-iskore nekro-infjammatorju u 8/26 (31 %) pazjenti marru għall-agħar meta mqabbla ma' qabel ma mbeda t-trattament.
English: The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim.
Maltese: partikolarment meta r-rotta ewlenija ta' minn fejn jitneħħew hi t-tnixxija attiva tal-kliewi minn ġo s-sistema ta' trasport katjonika organika eż. trimethropin.
English: How to take Zeffix
Maltese: X'fih Zeffix
English: There is a risk of your hepatitis getting worse (see section 2).
Maltese: Hemm riskju li l-epatite tiegħek tmur għall-agħar (ara sezzjoni 2).
English: Hypromellose
Maltese: Anġjoedima
English: Frequencies are defined as: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1000 to < 1/100), rare ( 1/10,000 to < 1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Maltese: Il-frekwenzi huma definiti hekk: komuni ħafna (≥ 1/10), komuni (≥ 1/100 sa < 1/10), mhux komuni (≥ 1/1000 sa < 1/100), rari (≥ 1/10,000
English: Renal impairment
Maltese: Reazzjoni allerġika
English: Zeffix 100 mg film-coated tablets lamivudine
Maltese: Pilloli Zeffix 100 mg Lamivudine
English: Contains amongst others: sugar (sucrose), preservatives: methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216)
Maltese: Zokkor (sucrose), priservattivi: methyl parahydroxybenzoate (E218) u propyl parahydroxybenzoate (E216)
English: ALT  2 x baseline value
Maltese: ALT ≥ 2 x valur linja bażi
English: Titanium dioxide
Maltese: Aċidożi lattika
English: Currently available data are described in sections 4.4 and 5.1 but no recommendation on a posology can be made.
Maltese: Dejta disponibbli attwalment hi deskritta fis-sezzjonijiet 4.4 u 5.1 imma l-ebda rakkomandazzjoni fuq il-pożoloġija ma tista' tingħata.
English: A modest increase in Cmax (28 %) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) was not significantly altered.
Maltese: Żieda diskreta ta' Cmax (28%) ġiet osservata għal zidovudine meta jittieħed ma' lamivudine, biss lesponiment ġenerali (AUC) ma tbiddlitx sostanzjalment.
English: Latvija GlaxoSmithKline Latvia SIA
Maltese: GlaxoSmithKline Lietuva UAB
English: However, disease progression in YMDD subjects in the lamivudine group was lower than the disease progression in the placebo group (23/209, 11 % versus 38/214, 18 % respectively).
Maltese: Madankollu, l-iżvilupp tal-marda f'suġġetti b'YMDD fil-grupp tal-lamivudine kien anqas mill-iżvilupp tal-marda fil grupp plaċebo (23/209, 11 % kontra 38/214, 18 % rispettivament).
English: Lamivudine was not mutagenic in bacterial tests but, like many nucleoside analogues showed activity in an in vitro cytogenetic assay and the mouse lymphoma assay.
Maltese: Lamivudine ma kienx mutaġeniku f'testijiet ta' batterji, biss bħal ħafna analogi nucleosidi wera attivita' f'analiżi ċitoġenetika in vitro u f'analiżi ta' limfoma fil-ġurdien.
English: Lamivudine is an antiviral agent which is active against hepatitis B virus in all cell lines tested and in experimentally infected animals.
Maltese: Lamivudine huwa aġent antivirali attiv kontra l-virus ta' l-epatite B fil-linji kollha ta' ċelluli ttestjati u fl-annimali infettati b'esperiment.
English: Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Maltese: Analogi nukleosidi u nukleotidi jikkawżaw ħsara mitokondrijali varjabbli kemm in vitro u kemm in vivo.
English: * Zeffix oral solution containing 5 mg/ml lamivudine.
Maltese: * Soluzzjoni li tittieħed mill-ħalq Zeffix li jkun fiha 5 mg/ml lamivudine.
English: If you are diabetic, please note that each dose of Zeffix (100 mg = 20 ml) contains 4 g of sucrose.
Maltese: Jekk inti dijabetiku, jekk jogħġbok innota li kull doża ta' Zeffix (100 mg = 20 ml) fiha 4 g ta' sucrose.
English: For HIV co-infected patients not requiring anti-retroviral therapy, there is a risk of HIV mutation when using lamivudine alone for treating chronic hepatitis B.
Maltese: Għal pazjenti ko-infettati bl-HIV mingħajr il-bżonn ta' terapija anti retrovirali, hemm riskju ta' tibdil ta' l-HIV meta jintuża lamivudine waħdu għall-kura ta' l-epatite B kronika.
English: Any child exposed in utero to nucleoside and nucleotide analogues, should have clinical and laboratory follow-up and should be fully investigated for possible mitochondrial dysfunction in cases which have relevant signs or symptoms.
Maltese: Kull tarbija li ġiet esposta in utero għal analogi nukleosidi u nukleotidi għandha tibqa' tiġi ssorveljata klinikament u b'testijiet fil-laboratorju u għandha tkun investigata sew għal possibilità ta' disfunzjoni tal-mitokondrija jekk jidhru xi sinjali jew sintomi rilevanti.
English: Table 2: Efficacy results 5 years by YMDD status (Asian Study) NUCB3018
Maltese: Tabella 2: Riżultati ta' effikaċja 5 snin skond l-istatus ta' YMDD (Studju Asjatiku)
English: In assays relating to potential substance effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects.
Maltese: Fl-analiżi ta' l-effetti possibbli tas-sustanza fuq struttura mitokondrijali u l-kontenut u l-funzjoni ta' DNA, lamivudine ma nstabx li kellu xi effetti serji ta' tossiċita'.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
Maltese: Informazzjoni ddettaljata dwar din il-mediċina tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għall-Mediċini http://www.ema.europa.eu/
English: Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline.
Maltese: Attakki qawwija spontanji f'każijiet ta' epatite B kronika huma relattivament komuni u huma kkaratterizzati minn żjidiet temporanji f'ALT fis-serum.
English: HBeAg seroconversion was increased in patients with elevated ALT levels; 77 % (20/26) of patients with pre-treatment ALT > 2 x ULN seroconverted.
Maltese: Is-serokonverżjoni ta' l-HbeAg żdiedet f'pazjenti b'livelli għoljin ta' ALT. 77% (20/26) ta' pazjenti bl' ALT ta' qabel it-trattament >2x ULN kellhom serokonverżjoni.
English: • emtricitabine, used to treat HIV or hepatitis B infection
Maltese: • emtricitabine jintuża għall-kura ta' infezzjoni tal-HIV jew tal-epatite B)
English: The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA (23/209, 11 %) compared to those without detectable YMDD mutant HBV (11/221, 5 %).
Maltese: Irrata ta' l-iżvilupp totali tal-marda fil-grupp tal-lamivudine kienet ogħla f'dawk is-suġġetti bilmutant YMDD tal-HBV DNA li jista' jiġi osservat (23/209, 11 %) meta mqabbla ma' dawk mingħajr il-mutant YMDD tal-HBV li jista' jiġi osservat (11/221, 5 %).
English: In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml compared to a median increase of 0.3 log10 copies/ml in those patients receiving lamivudine monotherapy.
Maltese: Fi studju double-blind f'pazjenti b'CHB bil-mutant YMDD tal-HBV u b'mard ikkumpensat tal fwied (NUC20904), b'rispons viroloġiku u bijokimiku għal lamivudine mnaqqas (n=95), iż-żieda ta' adefovir dipivoxil 10 mg darba kuljum flimkien ma' terapija b'lamivudine 100mg għal 52
English: It has a very low potential to decrease mitochondrial DNA content, is not permanently incorporated into mitochondrial DNA, and does not act as an inhibitor of mitochondrial DNA polymerase gamma.
Maltese: Għandu potenzjal baxx ferm biex inaqqas il-kontenut ta' DNA mitochondrial, ma jsirx parti permanenti ta' DNA mitochondrial, u ma jaħdimx bħala inibitur ta' mitochondrial DNA polymerase gamma.
English: Thrombocytopenia Metabolism and nutrition disorders Very rare
Maltese: Disturbi fil-metaboliżmu u n-nutrizzjoni
English: Co-administration of lamivudine with food resulted in a delay of tmax and a lower Cmax (decreased by up to 47 %).
Maltese: It-teħid ta' lamivudine ma' l-ikel irriżulta f'dewmien ta' tmax u ta' Cmax aktar baxx (tnaqqas sa 47%).
English: Limited data shows lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF).
Maltese: Tagħrif limitat juri li lamivudine jidħol fis-sistema ċentrali nervuża (CNS) u jilħaq il-fluwidu ċerebro-spinali (CSF).
English: Available human data from the Antiretroviral Pregnancy Registry reporting more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect.
Maltese: Dejta disponibbli fil-bniedem mir-Reġistru tat-Tqala Antiretrovirali li tirrapporta aktar minn 1000 riżultat mill-ewwel trimestru u aktar minn 1000 riżultat mit-tieni u t-tielet trimestru ta' esponiment fin-nisa tqal ma tindikax effett ta' malformazzjoni u effett fil-fetu/fit-tarbija tattwelid.
English: 100 mg once daily, Cmax is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml.
Maltese: Wara li din il-mediċina tkun ittieħdet mill-ħalq, il-ħin medju għal konċentrazzjonijiet massimi (tmax) ta' serum hu bejn wieħed u ieħor ta' 1.1-1.5 µg/ml u l-livelli t'isfel kienu 0.015-0.020 µg/ml.
English: Diabetic patients should be advised that each dose of oral solution (100 mg = 20 ml) contains 4 g of sucrose.
Maltese: (100 mg = 20 ml) fiha 4 g ta' sucrose.
English: Lamivudine-TP acts as a substrate for the HBV viral polymerase.
Maltese: Lamivudine huwa fil-biċċa l-kbira eliminat bit-tnixxija katjonika organika attiva.
English: The combination of lamivudine with cladribine is not recommended (see section 4.5).
Maltese: L-għoti ta' lamivudine ma' cladribine mhux irrakkomandat (ara sezzjoni 4.5).
English: Zeffix should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).
Maltese: Zeffix m'għandux jittieħed flimkien ma' prodotti mediċinali oħra li fihom lamivudine jew prodotti mediċinali li fihom emtricitabine (ara sezzjoni 4.5).
English: ALT 2 x baseline value; and bilirubin >2 x ULN and 2 x baseline value *Each patient may be represented in one or more category.
Maltese: IU/L ALT ≥2 x valur linja bażi; u bilirubin >2 x ULN and
English: Zeffix helps to control your hepatitis B infection.
Maltese: Zeffix jgħin biex jikkontrolla l-infezzjoni tal-epatite B tiegħek.
English: Section 6).
Maltese: NUMRU(I)
English: When doses below 100 mg are required Zeffix oral solution should be used (see Table 1 below).
Maltese: Meta dożi ta' inqas minn 100 mg ikunu meħtieġa għandha tintuża t-taħlita likwida orali Zeffix (ara Tabella 1 hawn taħt).
English: Side effects thought to be caused by Zeffix A very common side effect (these may affect more than 1 in 10 people) which may show up in blood tests is:
Maltese: Effetti sekondarji maħsuba li huma kkawżati minn Zeffix Effett sekondarju komuni ħafna (dawn jistgħu jaffettwaw aktar minn persuna waħda minn kull 10) li jista' jidher fit-testijiet tad-demm huwa:
English: In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels.
Maltese: F'pazjenti b'CHB pożittiva għal HBeAg jew negattiva għal HBeAg, l-iżvilupp tal-mutant YMDD (tyrosine-methionine-aspartate-aspartate) tal-HBV jista' jirriżulta f'rispons terapewtiku mnaqqas għal lamivudine, indikat minn żieda f'HBV DNA u fl-ALT mil-livelli ta' waqt il-kura ta' qabel.
English: - Week 260 negative positive < baseline positive > baseline
Maltese: negattiv pożittiv < linja bażi pożittiv > linja bażi
English: Consider more frequent monitoring of HBV viral load when chronic co-administration cannot be avoided.
Maltese: Ikkunsidra monitoraġġ aktar frekwenti tat-tagħbija virali tal-HBV meta t-teħid kroniku ma jkunx jista' jiġi evitat.
English: • In patients with HBeAg negative CHB (pre-core mutant) without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Maltese: • F'pazjenti b'CHB negattiva għall-HbeAg (mutant pre-core) mingħajr ċirrożi, it-trattament għandu jingħata għallinqas sas-serokonverżjoni tal-HBs jew sa meta jkun hemm evidenza li m'għadux aktar effettiv.
English: Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA.
Maltese: Attakk qawwi ta' epatite kien osservat f'pazjenti li waqqfu t-terapija ta' epatite B, u normalment huwa osservat għax ALT jogħla fis-serum u titfaċċa mill-ġdid l-HBV-DNA.
English: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Maltese: Pazjenti li minħabba problemi ereditarji rari, ma jaqbilx magħhom il-fructose, jew li għandhom problema ta' assorbiment ta' glucose u galactose jew insuffiċjenza ta' sucrase-isomaltase, m'għandhomx jieħdu din il-mediċina.
English: This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit.
Maltese: Dan il grad ta' soppressjoni virali inżamm (studju NUC20917 ta' wara) b'terapija kkombinata fit-tieni sena ta' kura sa ġimgħa 104 u l-biċċa l-kbira tal-pazjenti kellhom titjib fil-markaturi tal-funzjoni tal-fwied u komplew jiksbu benefiċċju kliniku.
English: When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76 - 100 %.
Maltese: Meta tkompliet il-kura b'lamivudine wara trapjant kien hemm tnaqqis ta' re-infezzjoni tal-graft bl-HBV, żieda f'telf ta' HbsAg u fuq rata ta' sena ta' sopravivenza ta' 76-100%.
English: The dosage should, therefore, be reduced for patients with a creatinine clearance of < 50 ml/minute.
Maltese: Id-dożaġġ għandu għalhekk jitnaqqas f'pazjenti bi tneħħija ta' kreatinina ta' <50 ml/minuta.
English: NAME OF THE MEDICINAL PRODUCT Zeffix 5 mg/ml oral solution Lamivudine
Maltese: Informazzjoni għall-utent Zeffix 5 mg/ml Soluzzjoni li tittieħed mill-ħalq lamivudine
English: Method of administration Oral use.
Maltese: Il-pakkett fih applikatur orali.
English: However, relapse following seroconversion can occur.
Maltese: Madankollu, wieħed jista jirkadi wara li jkun hemm serokonverżjoni.
English: In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min.
Maltese: F'pazjenti anzjani, minkejja li normalment ix-xjuħija ġġib tnaqqis fil-funzjoni tal-kliewi , m'hemmx effett klinikament sinifikanti fuq l-esponiment ta' lamivudine, ħlief f'pazjenti b'eliminazzjoni tal-krejatinina ta' <50 ml/min.